Brexanolone - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for brexanolone and what is the scope of patent protection?
Brexanolone
is the generic ingredient in one branded drug marketed by Sage Therap and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.Brexanolone has one hundred and twenty-six patent family members in thirty-two countries.
Summary for brexanolone
International Patents: | 126 |
US Patents: | 8 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 56 |
Clinical Trials: | 11 |
Patent Applications: | 1,004 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for brexanolone |
What excipients (inactive ingredients) are in brexanolone? | brexanolone excipients list |
DailyMed Link: | brexanolone at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for brexanolone
Generic Entry Date for brexanolone*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for brexanolone
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Brii Biosciences Limited | Phase 1 |
Sage Therapeutics | Phase 2 |
Brigham and Women's Hospital | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for brexanolone
US Patents and Regulatory Information for brexanolone
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sage Therap | ZULRESSO | brexanolone | SOLUTION;INTRAVENOUS | 211371-001 | Jun 17, 2019 | DISCN | Yes | No | ⤷ Try for Free | ⤷ Try for Free | Y | ⤷ Try for Free | |||
Sage Therap | ZULRESSO | brexanolone | SOLUTION;INTRAVENOUS | 211371-001 | Jun 17, 2019 | DISCN | Yes | No | ⤷ Try for Free | ⤷ Try for Free | Y | ⤷ Try for Free | |||
Sage Therap | ZULRESSO | brexanolone | SOLUTION;INTRAVENOUS | 211371-001 | Jun 17, 2019 | DISCN | Yes | No | ⤷ Try for Free | ⤷ Try for Free | Y | ⤷ Try for Free | |||
Sage Therap | ZULRESSO | brexanolone | SOLUTION;INTRAVENOUS | 211371-001 | Jun 17, 2019 | DISCN | Yes | No | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
Sage Therap | ZULRESSO | brexanolone | SOLUTION;INTRAVENOUS | 211371-001 | Jun 17, 2019 | DISCN | Yes | No | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
Sage Therap | ZULRESSO | brexanolone | SOLUTION;INTRAVENOUS | 211371-001 | Jun 17, 2019 | DISCN | Yes | No | ⤷ Try for Free | ⤷ Try for Free | Y | ⤷ Try for Free | |||
Sage Therap | ZULRESSO | brexanolone | SOLUTION;INTRAVENOUS | 211371-001 | Jun 17, 2019 | DISCN | Yes | No | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for brexanolone
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 2020201919 | ⤷ Try for Free | |
San Marino | T202000008 | ⤷ Try for Free | |
Japan | 2012072160 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITION | ⤷ Try for Free |
European Patent Office | 3426257 | STÉROÏDES NEUROACTIFS, COMPOSITIONS, ET LEURS UTILISATIONS (NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF) | ⤷ Try for Free |
Japan | 4923144 | ⤷ Try for Free | |
Australia | 2022202943 | ⤷ Try for Free | |
South Korea | 20110010742 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | ⤷ Try for Free |
>Country | >Patent Number | >Title | >Estimated Expiration |
Market Dynamics and Financial Trajectory for Brexanolone
More… ↓